Initiating or Switching to Insulin Degludec/Insulin Aspart in Adults with Type 2 Diabetes: A Real-World, Prospective, Non-interventional Study Across Six Countries

INTRODUCTION: Insulin degludec/insulin aspart (IDegAsp) is a fixed-ratio co-formulation of insulin degludec (a basal insulin) and insulin aspart (a prandial insulin). The aim of this study was to investigate clinical outcomes in people with type 2 diabetes (T2D) after initiating IDegAsp treatment in...

Descripción completa

Detalles Bibliográficos
Autores principales: Fulcher, Gregory R., Akhtar, Shahid, Al-Jaser, Saleh J., Medina, Johan, Mohamed, Mafauzy, Nicodemus, Nemencio A., Olsen, Anne Helene, Singh, Kiran P., Kok, Adri
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9244059/
https://www.ncbi.nlm.nih.gov/pubmed/35752730
http://dx.doi.org/10.1007/s12325-022-02212-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9244059/
https://www.ncbi.nlm.nih.gov/pubmed/35752730
http://dx.doi.org/10.1007/s12325-022-02212-3

Ejemplares similares